Curaleaf (OTCMKTS:CURLF) Rating Increased to Moderate Buy at Cormark

Curaleaf (OTCMKTS:CURLF) was upgraded by research analysts at Cormark from a “hold” rating to a “moderate buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. Cormark also issued estimates for Curaleaf’s FY2024 earnings at ($0.25) EPS and FY2025 earnings at ($0.18) EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th.

Curaleaf Stock Down 0.5 %

OTCMKTS:CURLF opened at $3.12 on Monday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.72 and a quick ratio of 0.36. Curaleaf has a one year low of $2.51 and a one year high of $6.40. The firm’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $4.70. The company has a market cap of $2.02 billion, a PE ratio of -8.00 and a beta of 0.88.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.43% and a negative net margin of 20.29%. The company had revenue of $342.29 million for the quarter, compared to the consensus estimate of $344.57 million. On average, research analysts anticipate that Curaleaf will post -0.21 earnings per share for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.